Login

Financial Snapshot

Revenue
TTM
$3.565M
Gross Margin
TTM
34.21%
Net Income
TTM
-$15.74M
Current Assets
2026 Q1
$12.12M
Current Liabilities
2026 Q1
$4.804M
Current Ratio
2026 Q1
252.37%
Total Assets
2026 Q1
$13.30M
Total Liabilities
2026 Q1
$4.809M
Book Value
2026 Q1
8.494M
Cash
2026 Q1
$8.115M
P/E
Last 4 Quarters
N/A
Free Cash Flow
TTM
-$14.89M

Stock Price

Loading...
Market Cap: $10.421 Million

About Icecure Medical Ltd

IceCure Medical Ltd. engages in the development and marketing of therapy for the treatment of tumors. The firm operates as commercial stage medical device company focusing on the research, development and marketing of cryoablation systems, disposables and technologies based on liquid nitrogen, or LN2, for treating tumors. Cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in breast, lungs, kidneys, bones and other indications. Company's lead product is ProSense system, a single probe system, but in addition the Company developed an additional multi probe system that is expected to have the ability to freeze several tumors simultaneously or larger tumors, named MultiSense system, which has not yet been commercialized.

Industry: Surgical & Medical Instruments & Apparatus Peers: Alpha Tau Medical Ltd Nano-X Imaging Ltd

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support